Amag Pharmaceuticals to buy Cord Blood Registry

Published On 2015-07-02 07:27 GMT   |   Update On 2015-07-02 07:27 GMT

Amag Pharmaceuticals announced on Monday that it plans to buy Cord Blood Registry. The privately owned stem cell bank is being purchased for a whopping $700 million.CBR houses preserves umblical cord blood and tissue sections. According to a statement released by Amag, it currently houses more than 6,00,000 units, a considerable fraction of all units in US.The majority of Amag...

Login or Register to read the full article
Amag Pharmaceuticals announced on Monday that it plans to buy Cord Blood Registry. The privately owned stem cell bank is being purchased for a whopping $700 million.

CBR houses preserves umblical cord blood and tissue sections. According to a statement released by Amag, it currently houses more than 6,00,000 units, a considerable fraction of all units in US.

The majority of Amag Pharmaceuticals' profits come from Makena, a drug used to reduce risk of premature delivery in pregnant women. It is also involved in producing medication used in oncology and patients of anemia.

The pharmaceutical company is optimistic about its prospects. It predicts immediate profits from CBR.

Amag Pharmaceuticals primarily makes, Feraheme  (Ferumoxytol) used to treat iron deficiency anaemia and CKD.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News